Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that CD30 + status confers therapeutic sensitivity to Brentuximab vedotin in patients with Hodgkin Lymphoma.

The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkins Lymphoma (HL) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.

This statement is based on a regulatory approval from the Health Service Executive:

Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option

Citation

Brentuximab vedotin Monotherapy, 2025, version number 6, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6333/234_v6_Brentuximab.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2014-08-01	Health Service Executive	Indication approved for reimbursement.